{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:57Z","timestamp":1764510417659},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T00:00:00Z","timestamp":1313625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11899-011-0096-8","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T15:32:58Z","timestamp":1313595178000},"page":"245-250","source":"Crossref","is-referenced-by-count":56,"title":["CD30+ Neoplasms of the Skin"],"prefix":"10.1007","volume":"6","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,18]]},"reference":[{"key":"96_CR1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768\u201385.","journal-title":"Blood"},{"issue":"5","key":"96_CR2","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood.V74.5.1678.1678","volume":"74","author":"R Schwarting","year":"1989","unstructured":"Schwarting R, Gerdes J, D\u00fcrkop H, Falin B, Pileri S, Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74(5):1678\u201389.","journal-title":"Blood"},{"issue":"3","key":"96_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/PAI.0b013e3181c81d31","volume":"18","author":"SK Lau","year":"2010","unstructured":"Lau SK, Thomas P, Weiss LM. Immunohistochemical evaluation of CON6D\/B5: a new CD30 monoclonal antibody. Appl Immunohistochem Mol Morphol. 2010;18(3):273\u20137.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"96_CR4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/eji.1830190125","volume":"19","author":"O Josimovic-Alasevic","year":"1989","unstructured":"Josimovic-Alasevic O, Durkop H, Schwarting R, Back\u00e9 E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989;19(1):157\u201362.","journal-title":"Eur J Immunol"},{"issue":"6","key":"96_CR5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1440-1827.1994.tb01706.x","volume":"44","author":"K Miyake","year":"1994","unstructured":"Miyake K, Yoshino T, Sarker AB, Teramoto N, Akagi T. CD30 antigen in non-Hodgkin\u2019s lymphoma. Pathol Int. 1994;44(6):428\u201334.","journal-title":"Pathol Int"},{"key":"96_CR6","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.4049\/jimmunol.165.9.5105","volume":"165","author":"H Muta","year":"2000","unstructured":"Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol. 2000;165:5105\u201311.","journal-title":"J Immunol"},{"key":"96_CR7","doi-asserted-by":"crossref","unstructured":"Umeda K, Sun X, Guo Y, Yamada H, Shibata K, Yoshikai Y. Innate memory phenotype CD4(+) T cells play a role in early protection against infection with Listeria monocytogenes in a CD30L-dependent manner. Microbiol Immunol 2011 Jun 24 (Epub ahead of print).","DOI":"10.1111\/j.1348-0421.2011.00362.x"},{"issue":"6","key":"96_CR8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1084\/jem.20020319","volume":"196","author":"M Saraiva","year":"2002","unstructured":"Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type I cytokine-mediated inflammation by a Solubel CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med. 2002;196(6):829\u201339.","journal-title":"J Exp Med"},{"key":"96_CR9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1096\/fasebj.9.1.7821763","volume":"9","author":"G Prete Del","year":"1995","unstructured":"Del Prete G, De Carli M, Almerigogna F, Daniel CK, D\u2019Elios MM, Zancuoghi G, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995;9:81\u20136.","journal-title":"FASEB J"},{"issue":"1","key":"96_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/archderm.97.1.23","volume":"97","author":"WL Macaulay","year":"1968","unstructured":"Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign -- histologically malignant. Arch Dermatol. 1968;97(1):23\u201330.","journal-title":"Arch Dermatol"},{"issue":"8","key":"96_CR11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e3181e75356","volume":"34","author":"A Saggini","year":"2010","unstructured":"Saggini A, Gulia A, Argenyi Z, Fink-Puches R, Lissia A, Maga\u00f1a M, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol. 2010;34(8):1168\u201375.","journal-title":"Am J Surg Pathol"},{"key":"96_CR12","doi-asserted-by":"crossref","unstructured":"\u2022 Morimura S, Sugaya M, Tamaki Z, Takekoshi T, Sato S. lymphomatoid papulosis showing \u03b3\u03b4 T-cell phenotype. Acta Derm Venereol 2011 Jun 1 (Epub ahead of print). This reference and reference [11] introduces the concept of LyP having CD8+ or \u03b3\u03b4 T-cell phenotypes and the need to separate these types from more aggressive tumors.","DOI":"10.2340\/00015555-1145"},{"key":"96_CR13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1749-6632.2001.tb03711.x","volume":"941","author":"ME Kadin","year":"2001","unstructured":"Kadin ME, Levi E, Kempf W. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann N Y Acad Sci. 2001;941:59\u201368.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"96_CR14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2133.2000.03656.x","volume":"143","author":"O Zoi-Toli","year":"2000","unstructured":"Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol. 2000;143(2):313\u20139.","journal-title":"Br J Dermatol"},{"issue":"12","key":"96_CR15","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","volume":"95","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653\u201361.","journal-title":"Blood"},{"issue":"5","key":"96_CR16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2008.03024.x","volume":"34","author":"J Kunishige","year":"2009","unstructured":"\u2022 Kunishige J, McDonald H, Alvarez G, Johnson M, Prieto V, Duvic M. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009;34(5):576\u201381. This is the most recent large case series of LyP patients, showing a secondary malignancy rate of 40% and multivariable risk factor analysis.","journal-title":"Clin Exp Dermatol"},{"key":"96_CR17","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","volume":"96","author":"H Stein","year":"2000","unstructured":"Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30+ anaplastic large T-cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681\u201395.","journal-title":"Blood"},{"issue":"4","key":"96_CR18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/modpathol.2010.225","volume":"24","author":"DA Wada","year":"2011","unstructured":"Wada DA, Law ME, Hsi ED, Ma L, Lim MS, Souza A, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596\u2013605.","journal-title":"Mod Pathol"},{"issue":"3","key":"96_CR19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0037-1963(03)00138-0","volume":"40","author":"ME Kadin","year":"2003","unstructured":"Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003;40(3):244\u201356.","journal-title":"Semin Hematol"},{"issue":"5","key":"96_CR20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood.V88.5.1771.1771","volume":"88","author":"AH Sarris","year":"1996","unstructured":"Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, et al. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin\u2019s lymphomas, Hodgkin\u2019s disease, or lymphomatoid papulosis. Blood. 1996;88(5):1771\u20139.","journal-title":"Blood"},{"issue":"5 Pt 2","key":"96_CR21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/jd.1999.v40.a95960","volume":"40","author":"MM Tomaszewski","year":"1999","unstructured":"Tomaszewski MM, Moad JC, Lupton GP. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood. J Am Acad Dermatol. 1999;40(5 Pt 2):857\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"96_CR22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/PAS.0b013e318162bcc1","volume":"32","author":"AK Wong","year":"2008","unstructured":"Wong AK, Lopategui J, Clancy S, Kulber D, Bose S. Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature. Am J Surg Pathol. 2008;32(8):1265\u20138.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"96_CR23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/PRS.0b013e318199edeb","volume":"123","author":"L Lipworth","year":"2009","unstructured":"Lipworth L, Tarone RE, McLaughlin JK. Breast implants and lymphoma risk: a review of the epidemiologic evidence through 2008. Plast Reconstr Surg. 2009;123(3):790\u20133.","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"96_CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0560.1995.tb00743.x","volume":"22","author":"L Cerroni","year":"1995","unstructured":"Cerroni L, Beham-Schmid C, Kerl H. Cutaneous Hodgkin\u2019s disease: an immunohistochemical analysis. J Cutan Pathol. 1995;22(3):229\u201335.","journal-title":"J Cutan Pathol"},{"issue":"3","key":"96_CR25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","volume":"126","author":"R Talpur","year":"2006","unstructured":"Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(3):575\u201383.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"96_CR26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3816\/CLM.2004.n.025","volume":"5","author":"AG Perna","year":"2004","unstructured":"Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic large cell lymphoma of the small bowel. Clin Lymphoma. 2004;5(3):190\u20133.","journal-title":"Clin Lymphoma"},{"key":"96_CR27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0190-9622(93)70140-O","volume":"28","author":"R Willemze","year":"1993","unstructured":"Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28:973\u201380.","journal-title":"J Am Acad Dermatol"},{"key":"96_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaad.2003.12.028","volume":"51","author":"JM Shehan","year":"2004","unstructured":"Shehan JM, Kalaaji AN, Markovic SN, Ahmed I. Management of multifocal primary cutaneous CD30+ anaplastic large cell lymphoma. J Am Acad Dermatol. 2004;51:103\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"96_CR29","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","volume":"15","author":"M Duvic","year":"2009","unstructured":"Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15(19):6217\u201324.","journal-title":"Clin Cancer Res"},{"issue":"19)","key":"96_CR30","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"\u2022 Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19)):1812\u201321. This article, of outstanding importance, shows the efficacy of SGN-35, a novel conjugated antibody that has high response rates in CD30+ tumors.","journal-title":"N Engl J Med"},{"issue":"6","key":"96_CR31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bmt.1704411","volume":"33","author":"S Ingen-Housz-Oro","year":"2004","unstructured":"Ingen-Housz-Oro S, Bachelez H, Verola O, Lebbe C, Marolleau JP, Hennequin C, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant. 2004;33(6):629\u201334.","journal-title":"Bone Marrow Transplant"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0096-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-011-0096-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0096-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T07:10:52Z","timestamp":1712733052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-011-0096-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,18]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1007\/s11899-011-0096-8","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,18]]}}}